Metronomic scheduling of anticancer treatment: The next generation of multitarget therapy?

Future Oncology

Volumn 7, Issue 3, 2011, Pages 385-394

  André, Nicolas ^a,b   Padovani, Laetitia ^b   Pasquier, Eddy ^c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

angiogenesis; cancer; drug repositioning; extracellular matrix; immune system; metronomic chemotherapy; multitarget therapy; pharmacology; resistance; tumor microenvironment

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CELECOXIB; CILENGITIDE; CYCLOPHOSPHAMIDE; DALTEPARIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; IMIDAZOLE; METHOTREXATE; PACLITAXEL; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RETINOIC ACID; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; VINBLASTINE;

BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; MELANOMA; METRONOMIC SCHEDULING OF ANTICANCER TREATMENT; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 79953159535     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.11     Document Type: Review

References (56)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(2), 1182-1186 (1971).
2. Hanna1 E, Quick J, Libutti SK: The tumour microenvironment: a novel target for cancer therapy. Oral Dis. 15(1), 8-17 (2009).
3. Albini A, Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 7(2), 139-147 (2007). (Pubitemid 46160989)
4. Gatenby RA, Gillies RJ: A microenvironmental model of carcinogenesis. Nat. Rev. Cancer 8(1), 56-61 (2008).
5. Meads MB, Gatenby RA, Dalton WS: Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9(9), 665-674 (2009).
6. Box C, Rogers SJ, Mendiola M, Eccles SA: Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin. Cancer Biol. 20(3), 128-138 (2010)
7. Sica A, Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117(5), 1155-1566 (2007).
8. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362(10), 875-885 (2010).
9. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14(5), 518-527 (2008). (Pubitemid 351655218)
10. Eyler CE, Rich JN: Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26(17), 2839-2844 (2008).
11. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ: Cancer stem cells: how can we target them? Curr. Med. Chem. 15(30), 3171-3184 (2008).
12. Abdollahi A, Folkman J: Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist. Updat. 13(1-2), 16-28 (2010).
13. André N, Pasquier E, Gentet JC, Kamen B: Looking at the seemingly contradictory role vinblastine in anaplastic large cell lymphoma from a ?metronomic? perspective. J. Clin. Oncol. 29(4), E90-E91 (2011).
14. Zimmermann GR, Lehár J, Keith CT: Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12(1-2), 34-42 (2007). (Pubitemid 46014485)
15. Gatenby RA: A change of strategy in the war on cancer. Nature 459(7246), 508-509 (2009).
16. André N, Pasquier E: For cancer, seek and destroy or live and let live? Nature 460(7253), 324 (2009).
17. Vassal G: Has chemotherapy reached its limits in pediatric cancers? Eur. J. Cancer 41(4), 564-575; discussion 576-577 (2005). (Pubitemid 40292736)
18. Savage P, Stebbing J, Bower M, Crook T: Why does cytotoxic chemotherapy cure only some cancers? Nat. Clin. Pract. Oncol. 6(1), 43-52 (2009).
19. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised Phase 3 trial. Lancet Oncol. 11(10), 942-949 (2010).
20. Fidias P, Novello S: Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28(34), 5116-5123 (2010).
21. Mok TS, Ramalingam SS: Maintenance therapy in non small-cell lung cancer: a new treatment paradigm. Cancer 115(22), 5143-5154 (2009).
22. Brugieres L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J. Clin. Oncol. 27(30), 5056-5061 (2009).
23. Pasquier E, Kavallaris M, André N: Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7(8), 455-465 (2010).
24. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60(7), 1878-1886 (2000). (Pubitemid 30207647)
25. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105(8), R15-R24 (2000). (Pubitemid 30217701)
26. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4(6), 23-36 (2004).
27. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105(8), 1045-1047 (2000). (Pubitemid 30217688)
28. Gasparini G: Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2(12), 733-740 (2001). (Pubitemid 33134058)
29. Klement GL, Kamen BA: Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? J. Pediatr. Hematol. Oncol. 33(1), 1-3 (2011)
30. Palmberg E, Johnsen JI, Paulsson J, et al. Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int. J. Cancer. 124(5), 1227-1234 (2009).
31. Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J. Pediatr. Hematol. Oncol. 27(11), 573-581 (2005). (Pubitemid 41697342)
32. Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie 29(7), 308-313 (2006). (Pubitemid 44022404)
33. André N, Rome A, Coze C, et al. Metronomic etoposide/ cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clin. Ther. 30(7), 1336-1340 (2008).
34. López-Aguilar E, Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, et al. Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children. Arch. Med. Res. 39(7), 655-662 (2008).
35. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J. Clin. Invest. 118(6), 1991-2001 (2008). (Pubitemid 351872317)
36. Javeed A, Ashraf M, Riaz A, et al. Paclitaxel and immune system. Eur. J. Pharm. Sci. 38(4), 283-290 (2009).
37. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A: Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 69(17), 6987-6994 (2009).
38. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007). (Pubitemid 46348738)
39. Banissi C, Ghiringhelli F, Chen L, Carpentier AF: Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother. 58(10), 1627-1634 (2009).
40. Lang S, Picu A, Hofmann T, et al. COX inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectors. Int. J. Immunopathol. Pharmacol. 19(2), 409-419 (2006). (Pubitemid 44181963)
41. Pearce EL, Walsh MC, Cejas PJ, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460(7251), 103-107 (2009).
42. Wong NS, Buckman RA, Clemons M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J. Clin. Oncol. 28(5), 723-730 (2010).
43. Fousseyni T, Diawara M, Pasquier E, André N: Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01. J. Pediatr. Hematol. Oncol. 33(1), 31-34 (2011).
44. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Franaise d?Oncologie Pédiatrique. J. Clin. Oncol. 21(6), 1074-1081 (2003). (Pubitemid 46594136)
45. Shaikh AJ, Masood N: Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report. J. Med. Case Reports 4(1), 274 (2010).
46. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010)
47. Schönthal AH: Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 97(11), 1465-1468 (2007). (Pubitemid 350175844)
48. Panigrahy D, Kaipainen A, Huang S, et al. PPARa agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl Acad. Sci. USA 105(3), 985-990 (2008). (Pubitemid 351282068)
49. Saulnier Sholler GL, Kalkunte S, Greenlaw C, McCarten K, Forman E: Antitumor activity of nifurtimox observed in a patient with neuroblastoma. J. Pediatr. Hematol. Oncol. 28(10), 693-695 (2006). (Pubitemid 44536052)
50. Saulnier Sholler GL, Brard L, Straub JA, et al. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J. Pediatr. Hematol. Oncol. 31(3), 187-193 (2009).
51. Saulnier Sholler GL, Bergendahl GM, Brard L, et al. A Phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. J. Pediatr. Hematol. Oncol. 33(1), 25-30 (2011).
52. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11(1-2), 32-50 (2008).
53. Blansfield JA, Caragacianu D, Alexander HR 3rd, et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin. Cancer Res. 14(1), 270-280 (2008). (Pubitemid 351384377)
54. Noberasco C, Spitaleri G, Mancuso P, et al. Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. Oncology 77(6), 358-365 (2009).
55. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6(6), 327-338 (2009).
56. Bertolini F, Marighetti P, Shaked Y: Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate post-resistance therapy. Biochim. Biophys. Acta 1806(2), 131-137 (2010).